Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.
about
Anti-angiogenesis and metastasis: a tumour and stromal cell allianceCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceAddition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.Systemic adjuvant therapies in renal cell carcinomaHereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillanceAntiangiogenic therapy: impact on invasion, disease progression, and metastasis.Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib.Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
P2860
Q26862741-F927206B-115F-4FA5-A164-4FAF69705100Q28072166-E19CF103-848D-453B-9FA3-A059BA108C54Q33394138-3D114613-633C-4E8B-B113-B68179D0B3BEQ35295368-760B8BAA-13D4-47CE-9C21-416DE7F82BAAQ35569322-BD7B457A-0632-4804-A459-53EFF41D6A5AQ35815727-60A321BB-0EDC-423B-A0A7-7CF1E4D36617Q35966757-91E3CABC-67C0-44F1-885B-4B23CC6C7088Q36192083-CCDDDC45-D776-428C-ABF4-09FA2F12F19FQ36959106-D4C27572-3659-4364-B362-A3E5B3555F5DQ38835745-C2CCD8E4-3639-447E-9CA6-9D64A5FF8AF7Q41716525-68C4EF8B-A804-403F-9B81-3C9FC5057DC7Q41948917-99F56084-F1F2-41F5-B8CF-0AA9CFC9386CQ42257155-EA8DD820-035A-4EB2-A8BC-DF3CCAE0C934Q45870426-A23A902E-6237-4F12-8034-3FEC780FB350Q58585071-46757F0A-060E-4C6C-8F8D-437A91BDB98B
P2860
Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Patterns of disease progressio ...... patterns and outcome measures.
@ast
Patterns of disease progressio ...... patterns and outcome measures.
@en
type
label
Patterns of disease progressio ...... patterns and outcome measures.
@ast
Patterns of disease progressio ...... patterns and outcome measures.
@en
prefLabel
Patterns of disease progressio ...... patterns and outcome measures.
@ast
Patterns of disease progressio ...... patterns and outcome measures.
@en
P2093
P2860
P356
P1433
P1476
Patterns of disease progressio ...... patterns and outcome measures.
@en
P2093
B Nebiyou Bekele
Elizabeth R Plimack
Eric Jonasch
Nizar Tannir
P2860
P304
P356
10.1002/CNCR.24211
P407
P577
2009-05-01T00:00:00Z